Patient Preferences in Hidradenitis Suppurativa Depend on Treatment Experience: Results from APProach-HS

Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with significant unmet therapeutic needs. However, information on patient preferences for HS therapies is hitherto scarce. Our aim was to investigate the impact of treatment experience on patient preferences for pharmacological and surgical treatment of HS using conjoint analysis. Patients and Methods: Discrete choice experiments were applied for the attributes treatment modality (tablets, subcutaneous injections, surgery with secondary intention healing or primary closure), probability of sustained therapeutic success, probability of mild or severe adverse events, and duration of treatment or wound healing. These attributes were subsequently correlated with treatment experience. Results: Overall, 216 patients with HS considered therapeutic success as most important (Relative Importance Score (RIS):36.2), followed by the treatment modality (RIS:24.0). Patients experienced with biologics favoured subcutaneous injections most (PWU:18.1 vs. -0.5, p=0.020), whereas biologic-naïve patients preferred tablets. Patients who had undergone surgery with secondary intention healing valued this approach (PWU:4.1 vs. -24.8, p=0.004) and therapeutic success (RIS:37.5 vs. 31.6, p=0.017) higher and the duration of wound healing lower (RIS:18.9 vs. 23.3, p=0.037) than others. Conclusion: Individual preferences were depending significantly on treatment experience. Incorporation of this aspect could help to improve personalized care of patients with HS.

Authors

Institutions

Publication Details

Journal
Patient Preference and Adherence
Published
2026-04-01
DOI
https://doi.org/10.2147/ppa.s593382
Primary Topic
Hidradenitis Suppurativa and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patient Preferences in Hidradenitis Suppurativa Depend on Treatment Experience: Results from APProach-HS

Tatiana Görig, Christian Kromer, Dagmar Presser, Kristin Faverio et al.
Patient Preference and Adherence
Hidradenitis Suppurativa and Treatments
article

Patient Preferences in Hidradenitis Suppurativa Depend on Treatment Experience: Results from APProach-HS

Tatiana Görig, Christian Kromer, Dagmar Presser, Kristin Faverio, Friderike Benzel, Patrick Schummer, Rotraut Mössner, Wiebke K. Peitsch, W. Harth, Sylke Schneider-Burrus, Marthe-Lisa Schaarschmidt, Matthias Goebeler
article en

Abstract

Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with significant unmet therapeutic needs. However, information on patient preferences for HS therapies is hitherto scarce. Our aim was to investigate the impact of treatment experience on patient preferences for pharmacological and surgical treatment of HS using conjoint analysis. Patients and Methods: Discrete choice experiments were applied for the attributes treatment modality (tablets, subcutaneous injections, surgery with secondary intention healing or primary closure), probability of sustained therapeutic success, probability of mild or severe adverse events, and duration of treatment or wound healing. These attributes were subsequently correlated with treatment experience. Results: Overall, 216 patients with HS considered therapeutic success as most important (Relative Importance Score (RIS):36.2), followed by the treatment modality (RIS:24.0). Patients experienced with biologics favoured subcutaneous injections most (PWU:18.1 vs. -0.5, p=0.020), whereas biologic-naïve patients preferred tablets. Patients who had undergone surgery with secondary intention healing valued this approach (PWU:4.1 vs. -24.8, p=0.004) and therapeutic success (RIS:37.5 vs. 31.6, p=0.017) higher and the duration of wound healing lower (RIS:18.9 vs. 23.3, p=0.037) than others. Conclusion: Individual preferences were depending significantly on treatment experience. Incorporation of this aspect could help to improve personalized care of patients with HS.

Patient Preference and AdherenceVol. Volume 20
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Heidelberg University (DE), University Hospital Heidelberg (DE), Vivantes Klinikum (DE), Forschungsinstitut Havelhöhe (DE), Universitätsklinikum Würzburg (DE), Klinikum im Friedrichshain (DE), University Medical Centre Mannheim (DE), University of Göttingen (DE), Charité - Universitätsmedizin Berlin (DE)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, Biogen, Celgene, Array BioPharma, Les Laboratories Pierre Fabre, Mylan, Galderma, Sun Pharma, Medac, LEO Pharma, Novartis Pharma, UCB Pharma, Cilag
Zero hunger
Openalex Percentile: Top 30%
Hidradenitis Suppurativa and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.